-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hepatocellular carcinoma (HCC) is a serious global health problem.
Hepatocellular carcinoma (HCC) is a serious global health problem.
Recently, a combination therapy of atezolizumab (anti-PDL1) and bevacizumab (anti-VEGF) , an immune checkpoint inhibitor, has been approved as a first-line therapy for advanced HCC
immunity
Sorafenib and TRAIL-induced cell death
Sorafenib and TRAIL-induced cell deathThe researchers found that these two drugs can enhance the cell death effect induced by sorafenib, but this depends on the specific BH3-only protein
Sorafenib reduces the proliferation of Huh7 cells
Sorafenib reduces the proliferation of Huh7 cellsAll in all, the results of this study show that the expression of BH3-only protein determines the therapeutic response of HCC to different sorafenib drug combinations
The results of this study indicate that the expression of BH3-only protein determines the therapeutic response of HCC to different sorafenib drug combinations
BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment.
Leave a message here